9.06Open9.06Pre Close0 Volume7 Open Interest110.00Strike Price0.00Turnover343.43%IV60.11%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry9.06Extrinsic Value100Contract SizeAmericanOptions Type-0.0723Delta0.0007Gamma27.93Leverage Ratio-0.7165Theta-0.0130Rho-2.02Eff Leverage0.0793Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet